Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Protagenic Therapeutics Inc (PTIXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: PTIXW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 33.33% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 |
52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 491613 |
Shares Outstanding - | Shares Floating 491613 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Protagenic Therapeutics Inc
Company Overview
History and Background
Protagenic Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing novel peptide therapeutics. Further information regarding founding year and key milestones is not publicly available.
Core Business Areas
- Peptide Therapeutics Development: Development of novel peptide therapeutics for neurological disorders and other diseases with unmet medical needs.
Leadership and Structure
Details of Protagenic Therapeutics Inc's leadership team and organizational structure are not publicly available.
Top Products and Market Share
Key Offerings
- PT00114: PT00114 is a lead drug candidate by Protagenic Therapeutics currently under development. Market share and revenue data are not publicly available. Competitors are other companies developing treatments for neurological disorders.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Innovation and strategic partnerships are crucial for success.
Positioning
Protagenic Therapeutics Inc. is positioned as an emerging biopharmaceutical company focused on peptide therapeutics. Competitive advantages would depend on the success and patentability of its drug candidates.
Total Addressable Market (TAM)
The TAM depends on the specific indications targeted by Protagenic's drug candidates. Information on this is not publicly available. Their positioning depends on the efficacy and market penetration of their pipeline drugs.
Upturn SWOT Analysis
Strengths
- Novel peptide therapeutic approach
- Targeting unmet medical needs
Weaknesses
- Limited financial resources as a smaller biotech company
- Dependence on successful clinical trials
- No products currently on the market
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Failure in clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
Competitive Landscape
A complete competitive landscape is difficult to ascertain due to limited public information on Protagenic's specific therapeutic targets and competitors.
Growth Trajectory and Initiatives
Historical Growth: There is no historical growth data available for Protagenic Therapeutics Inc.
Future Projections: Future growth projections are not available due to limited public information.
Recent Initiatives: Recent strategic initiatives data are not publicly available.
Summary
Protagenic Therapeutics Inc. is a small biopharmaceutical company focused on developing peptide therapeutics. It faces typical challenges of early-stage biotech companies, including funding, regulatory hurdles, and competition. Positive clinical trial results and strategic partnerships are crucial for its success. Financials, market share and leadership information are not publicly available.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Industry reports
Disclaimers:
The information provided is based on limited publicly available data and should not be considered financial advice. This analysis is for informational purposes only. Market share data and other numerical values are estimates and should be verified with further research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-04-27 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.